Heartland Sneak Peek: HME Industry SWOT Analysis

Published in Government Relations on April 22, 2022

By Craig Douglas, Vice President, Payer and Member Relations, VGM Government Relations

The types and quantity of changes that have occurred within our industry over the past two years are unprecedented, and the majority of them have been driven by the COVID-19 pandemic. Some changes are legislative, some are regulatory, while others are payer policy/reimbursement related. Regardless of the type of change, they all impact your overall business strategy in some manner. These changes have made a profound impact on the DMEPOS industry as a whole, and most likely on your individual business as well. 

In the last 2 years, we’ve seen a Medicare competitive bid program that, for all intents and purposes, didn’t really happen for most of you, increased demand for certain products, policy changes from both CMS and private payers, reimbursement changes, supply chain issues, and product recalls that have impacted many DMEPOS providers.

From a cost perspective, several manufacturers have implemented either temporary surcharges or permanent price increases. These price increases are not limited to just a few manufacturers or a few products, but rather impact a large percentage of commonly requested DME product categories. In addition to the product cost changes, there have also been sharp increases in labor, shipping, fuel, and other overhead costs. There have also been new costs that weren’t there before, or that were previously minimal but are now much more substantial, such as PPE, temperature scanners, plastic barriers in the office, etc.

On the flip side of that, there have also been changes on the reimbursement side of things for many providers. Government program money (think Paycheck Protection Program, HHS Provider Relief Fund, etc.), as well as price increases from Medicare/Medicaid/private payers which helped offset some of the price increases providers were experiencing. Was there enough assistance? Was there too much? Many of those pricing changes are temporary, and there is still quite a bit of uncertainty surrounding the long-term reimbursement direction from the industry’s largest payer, CMS.

With all that has happened and that is yet to come, you may feel like you have more questions than answers in terms of what this looks like when ALL the dust settles.

Heartland LogoAt this year’s Heartland Conference, please join Craig Douglas, Ronda Buhrmester, Mark Higley, and John Gallagher from VGM as they discuss these topics, answer questions, and propose best practices and potential solutions to help your business thrive. Learn more and register at vgmheartland.com.   


TAGS

  1. billing & reimbursement
  2. cms
  3. heartland
  4. vgm government

From Our Experts

HR1 Passes House, Advances to President Trump's Desk for Signature thumbnail HR1 Passes House, Advances to President Trump's Desk for Signature After extensive negotiations and partisan debate, the House has officially passed HR1, clearing the path for the bill to be signed into law by President Donald Trump. The legislation, which aims to reduce federal healthcare expenditures, contains several provisions that may impact the durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) industry. CMS files the Proposed Rule that sheds light on the next round of the Competitive Bidding Program thumbnail CMS files the Proposed Rule that sheds light on the next round of the Competitive Bidding Program On June 30, 2025, CMS filed the anticipated Proposed Rule that includes updates to the Competitive Bidding Program (CBP). Public comments are due 60 days from June 30, 2025. Below is a high-level summary of the rule. It is critical to note that, according to the Proposed Rule Fact Sheet dated June 30, 2025, CMS has stated that they have not announced the specific product categories they are bidding or the specific timeframe for the next competition. Those specifics will be forthcoming in a fu Senate Narrowly Passes HR1, Sending It Back to House for Final Approval thumbnail Senate Narrowly Passes HR1, Sending It Back to House for Final Approval President Donald Trump's sweeping legislative package, formally titled the One Big, Beautiful Bill Act, now referred to as HR1., cleared the Senate today in a dramatic 51–50 vote, with Vice President JD Vance casting the tie-breaking vote. The bill now returns to the House, where lawmakers must decide whether to adopt the Senate's revised version or negotiate further changes before it can reach the president's desk. Several Prominent Medicaid Provisions in Senate's Budget Bill Deemed in Violation of Byrd Rule thumbnail Several Prominent Medicaid Provisions in Senate's Budget Bill Deemed in Violation of Byrd Rule Senate Parliamentarian Elizabeth MacDonough advised this week that multiple Medicaid provisions in the Senate's reconciliation bill would violate Senate procedure by violating the Byrd Rule. The Byrd Rule is a Senate-specific procedural process that allows Senators to prevent or block inclusion of extraneous provisions in reconciliation bills. Other provisions are still under review. Evaluating the Value of a Payer Contract thumbnail Evaluating the Value of a Payer Contract In our last article, Key Payers Denied Your Application Citing Their Network Is Closed – Now What?, we discussed strategies for addressing payer contracting denials due to a closed network. As indicated, this process can be an extremely time-consuming exercise with no guarantees and mixed results. Below are a few things to consider as you evaluate whether a contract is worth the extra effort. Webinar: Webinar: "Navigating The New CMS Landscape: RADs, HMVs, and Supplier Survival" on June 25 at 1 p.m. CT. The Centers for Medicare & Medicaid Services (CMS) has released its final National Coverage Determination (NCD) for RADs and HMVs used in treating chronic respiratory failure due to COPD. While the rule potentially expands access to bilevel ST therapy (RADs), it also introduces complex compliance requirements, tighter usage criteria, and increased documentation burdens—without additional reimbursement. The Return of Competitive Bidding thumbnail The Return of Competitive Bidding The Centers for Medicare & Medicaid Services (CMS) appear to be laying the groundwork for another round of the Competitive Bidding Program (CBP). While full implementation will take a couple of years, an official announcement is expected this summer—potentially as early as July. Out With The Old RAC, In With The New thumbnail Out With The Old RAC, In With The New On April 28, 2025, CMS awarded Cotiviti GOV Services LLC, the new RAC Recovery Audit Contractor (RAC) Region 3, 4, and 5 contracts. RAC Region 3 includes the following Medicare Administrative Contractor (MAC) jurisdictions: JJ, JM, and JN. RAC Region 4 includes jurisdictions: JE, JF, and JL. And RAC Region 5 includes jurisdictions: JA, JB, JC, JD, as well as the HH/H MACs: J6, J15, JK, and JM.